BioSpace News Archive

Many American physicians are wondering whether they still can be physicians. “We physicians have lost control of our profession, our patients’ safety, and our ability to freely practice patient-centered Hippocratic medicine in the United States,” writes San Antonio ophthalmologist Kristin Held, M.D., in the winter issue of the Journal of American Physicians and Surgeons.

FlowPlay, creator of the most powerful immersive gaming platform, today announced that its Vegas World in-game fundraisers have generated more than $100,000 for the American Cancer Society in 2019

Advicent announced today it has launched NaviPlan® 19.3, enabling financial professionals to leverage a robust healthcare dataset to deliver more accurate healthcare cost projections

Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced it has raised $30 million in a Series B financing led by new investor Sectoral Asset Management.

ams (SIX: AMS), a leading worldwide supplier of high-performance sensor solutions, is helping to make computed tomography (CT) scanners substantially more affordable.

The global automated suturing devices market was valued at US$ 867.3 million in 2027, and is projected to exhibit a CAGR of 5.3 % over the forecast period

HealthEC, LLC, the 2019 Best in KLAS provider of population health management solutions, announced that the firm has been recognized for its performance in KLAS’s newly published Population Health Care Management 2019 report, which examines the use of population health management software for care management.

Generex Biotechnology Corporation has issued a shareholder alert regarding recent trading activity that has adversely affected the company and its shareholders.

Median Technologies (Paris:ALMDT), The Imaging Phenomics Company (Euronext Growth – ALMDT) and the European Investment Bank (EIB) announced today the signing of a € 35 million finance contract, supported by the European Strategic Investment Fund (EFSI) or “Juncker Plan”.

NABH is both disappointed and frustrated that HHS and DOL act only when they receive information, thereby taking a reactionary approach to a law that affects the health of millions of Americans.